Lipocine Inc. announced that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. in the United States District Court related to the infringement of six Lipocine U.S. Patents by Clarus’s JATENZO® product, Lipocine has voluntarily dismissed its allegations of patent infringement for expired U.S. Patent Nos. 6,569,463 and 6,923,988.
February 11, 2020
· 3 min read